Check-Cap to merge with MBody AI in embodied AI workforce push
On Tuesday, UBS initiated coverage on Penumbra (NYSE:PEN), a medical technology company, with a Buy rating and a price target of $305.00. Trading at $263.69 and with a market capitalization of $10.12 billion, the stock is currently near its 52-week high of $277.34. The firm's analysts highlighted the company's robust new product launch cycle as a key factor that could drive significant revenue and profit growth in the near to medium term.
Penumbra's shares are expected to continue trading at a premium compared to its peers in the high-growth small to mid-cap (Smid-Cap) MedTech sector. This is supported by the company's impressive growth and margin profile, with InvestingPro data showing a robust gross profit margin of 63% and revenue growth of 17% over the last twelve months. UBS forecasts a compound annual growth rate (CAGR) of approximately 14% in revenue from 2024 to 2029, which is slightly higher than the consensus estimates of around 13%.
The company's sales outlook is considered particularly strong, with expectations of continued double-digit top-line growth. This optimistic forecast is supported by the launch of multiple new products that aim to expand the market. One of the significant growth opportunities identified for Penumbra is in the venous thromboembolism (VTE) market, which is currently underpenetrated.
UBS analysts believe that these new product launches will not only contribute to market expansion but will also provide a clear trajectory for the company's revenue and earnings growth. The firm's positive outlook on Penumbra underscores the potential for the stock to deliver strong returns for investors as the company capitalizes on these opportunities.
In other recent news, Penumbra, Inc. has been making headlines in the medical technology sector. Following the announcement of Stryker 's acquisition of Inari Medical (TASE:PMCN), Inc., Penumbra's shares climbed by 8.3%. Analysts, including Stifel's Matthew Blackman, perceive this acquisition as a positive development for Penumbra and the mechanical thrombectomy market as a whole.
In another development, Oppenheimer initiated coverage on Penumbra's shares with an Outperform rating and a price target of $275, citing the company's strong position in the market and the potential for robust mid-teens sales growth. Wells Fargo (NYSE:WFC) also upgraded Penumbra's stock from Equal Weight to Overweight, with a raised price target of $275, anticipating success in Penumbra's THUNDER trial and the market introduction of Thunderbolt in 2025.
Inari Medical Inc., on the other hand, received a rating downgrade from Buy to Hold from Jefferies, although the price target was increased to $80 following the announcement of Stryker Corporation (NYSE:SYK)'s acquisition agreement.
Meanwhile, RBC Capital Markets has projected a favorable outlook for the Medical Supplies & Devices sector, highlighting potential upside opportunities in stocks such as DexCom (NASDAQ:DXCM), Medtronic (NYSE:MDT), and Edwards Lifesciences (NYSE:EW). The firm's top large-cap picks for 2025 include Abbott Laboratories (NYSE:ABT), Boston Scientific (NYSE:BSX), Stryker Corporation, and Intuitive Surgical (NASDAQ:ISRG).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.